Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer

Baowei Fei, Olayinka A. Abiodun-Ojo, Akinyemi A. Akintayo, Oladunni Akin-Akintayo, Funmilayo Tade, Peter T. Nieh, Viraj A. Master, Mehrdad Alemozaffar, Adeboye O. Osunkoya, Mark M. Goodman, David M. Schuster

Research output: Contribution to journalArticle

Abstract

We assessed the feasibility and cancer detection rate of fluciclovine (18F) positron emission tomography-ultrasound fusion targeted biopsy vs standard template biopsy in the same patient with biochemical failure after nonsurgical therapy for prostate cancer.Materials and Methods:A total of 21 patients with a mean ± SD prostate specific antigen of 7.4 ± 6.8 ng/ml and biochemical failure after nonoperative prostate cancer treatment underwent fluciclovine (18F) positron emission tomography-computerized tomography (mean 364.1 ± 37.7 MBq) and planning transrectal prostate ultrasound with 3-dimensional image reconstruction. Focal prostatic activity on positron emission tomography was delineated and co-registered with planning ultrasound. During the subsequent biopsy session computer generated 12-core template biopsies were performed and then fluciclovine defined targets were revealed and biopsied. Histological analysis of template and targeted cores were completed.Results:Template biopsy was positive for malignancy in 6 of 21 patients (28.6%), including 10 of 124 regions and 11 of 246 cores, vs targeted biopsy in 10 of 21 (47.6%), including 17 of 50 regions and 40 of 125 cores. Five of 21 patients had positive findings on targeted biopsy only and 1 of 21 had positive findings on template biopsy only. An additional case was upgraded from Grade Group 2 to 3 on targeted biopsy. Extraprostatic disease was detected in 8 of 21 men (38.1%) with histological confirmation in all 3 who underwent lesion biopsy.Conclusions:Fluciclovine positron emission tomography real-time ultrasound fusion guidance for biopsy is feasible in patients with biochemical failure after nonsurgical therapy for prostate cancer. It identifies more recurrent prostate cancer using fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy of recurrent prostate cancer.

Original languageEnglish (US)
Pages (from-to)413-421
Number of pages9
JournalJournal of Urology
Volume202
Issue number2
DOIs
StatePublished - Aug 1 2019
Externally publishedYes

Fingerprint

Positron-Emission Tomography
Prostatic Neoplasms
Biopsy
Histocompatibility Antigens
Computer-Assisted Image Processing
Prostate-Specific Antigen
Prostate
Neoplasms
Therapeutics
Tomography

Keywords

  • diagnostic imaging
  • image-guided biopsy
  • positron emission tomography
  • prostatic neoplasms
  • ultrasonography

ASJC Scopus subject areas

  • Urology

Cite this

Feasibility and Initial Results : Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. / Fei, Baowei; Abiodun-Ojo, Olayinka A.; Akintayo, Akinyemi A.; Akin-Akintayo, Oladunni; Tade, Funmilayo; Nieh, Peter T.; Master, Viraj A.; Alemozaffar, Mehrdad; Osunkoya, Adeboye O.; Goodman, Mark M.; Schuster, David M.

In: Journal of Urology, Vol. 202, No. 2, 01.08.2019, p. 413-421.

Research output: Contribution to journalArticle

Fei, B, Abiodun-Ojo, OA, Akintayo, AA, Akin-Akintayo, O, Tade, F, Nieh, PT, Master, VA, Alemozaffar, M, Osunkoya, AO, Goodman, MM & Schuster, DM 2019, 'Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer', Journal of Urology, vol. 202, no. 2, pp. 413-421. https://doi.org/10.1097/JU.0000000000000200
Fei, Baowei ; Abiodun-Ojo, Olayinka A. ; Akintayo, Akinyemi A. ; Akin-Akintayo, Oladunni ; Tade, Funmilayo ; Nieh, Peter T. ; Master, Viraj A. ; Alemozaffar, Mehrdad ; Osunkoya, Adeboye O. ; Goodman, Mark M. ; Schuster, David M. / Feasibility and Initial Results : Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer. In: Journal of Urology. 2019 ; Vol. 202, No. 2. pp. 413-421.
@article{85e7b8ab881b415fa012af87d5b91f66,
title = "Feasibility and Initial Results: Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer",
abstract = "We assessed the feasibility and cancer detection rate of fluciclovine (18F) positron emission tomography-ultrasound fusion targeted biopsy vs standard template biopsy in the same patient with biochemical failure after nonsurgical therapy for prostate cancer.Materials and Methods:A total of 21 patients with a mean ± SD prostate specific antigen of 7.4 ± 6.8 ng/ml and biochemical failure after nonoperative prostate cancer treatment underwent fluciclovine (18F) positron emission tomography-computerized tomography (mean 364.1 ± 37.7 MBq) and planning transrectal prostate ultrasound with 3-dimensional image reconstruction. Focal prostatic activity on positron emission tomography was delineated and co-registered with planning ultrasound. During the subsequent biopsy session computer generated 12-core template biopsies were performed and then fluciclovine defined targets were revealed and biopsied. Histological analysis of template and targeted cores were completed.Results:Template biopsy was positive for malignancy in 6 of 21 patients (28.6{\%}), including 10 of 124 regions and 11 of 246 cores, vs targeted biopsy in 10 of 21 (47.6{\%}), including 17 of 50 regions and 40 of 125 cores. Five of 21 patients had positive findings on targeted biopsy only and 1 of 21 had positive findings on template biopsy only. An additional case was upgraded from Grade Group 2 to 3 on targeted biopsy. Extraprostatic disease was detected in 8 of 21 men (38.1{\%}) with histological confirmation in all 3 who underwent lesion biopsy.Conclusions:Fluciclovine positron emission tomography real-time ultrasound fusion guidance for biopsy is feasible in patients with biochemical failure after nonsurgical therapy for prostate cancer. It identifies more recurrent prostate cancer using fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy of recurrent prostate cancer.",
keywords = "diagnostic imaging, image-guided biopsy, positron emission tomography, prostatic neoplasms, ultrasonography",
author = "Baowei Fei and Abiodun-Ojo, {Olayinka A.} and Akintayo, {Akinyemi A.} and Oladunni Akin-Akintayo and Funmilayo Tade and Nieh, {Peter T.} and Master, {Viraj A.} and Mehrdad Alemozaffar and Osunkoya, {Adeboye O.} and Goodman, {Mark M.} and Schuster, {David M.}",
year = "2019",
month = "8",
day = "1",
doi = "10.1097/JU.0000000000000200",
language = "English (US)",
volume = "202",
pages = "413--421",
journal = "Journal of Urology",
issn = "0022-5347",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Feasibility and Initial Results

T2 - Fluciclovine Positron Emission Tomography/Ultrasound Fusion Targeted Biopsy of Recurrent Prostate Cancer

AU - Fei, Baowei

AU - Abiodun-Ojo, Olayinka A.

AU - Akintayo, Akinyemi A.

AU - Akin-Akintayo, Oladunni

AU - Tade, Funmilayo

AU - Nieh, Peter T.

AU - Master, Viraj A.

AU - Alemozaffar, Mehrdad

AU - Osunkoya, Adeboye O.

AU - Goodman, Mark M.

AU - Schuster, David M.

PY - 2019/8/1

Y1 - 2019/8/1

N2 - We assessed the feasibility and cancer detection rate of fluciclovine (18F) positron emission tomography-ultrasound fusion targeted biopsy vs standard template biopsy in the same patient with biochemical failure after nonsurgical therapy for prostate cancer.Materials and Methods:A total of 21 patients with a mean ± SD prostate specific antigen of 7.4 ± 6.8 ng/ml and biochemical failure after nonoperative prostate cancer treatment underwent fluciclovine (18F) positron emission tomography-computerized tomography (mean 364.1 ± 37.7 MBq) and planning transrectal prostate ultrasound with 3-dimensional image reconstruction. Focal prostatic activity on positron emission tomography was delineated and co-registered with planning ultrasound. During the subsequent biopsy session computer generated 12-core template biopsies were performed and then fluciclovine defined targets were revealed and biopsied. Histological analysis of template and targeted cores were completed.Results:Template biopsy was positive for malignancy in 6 of 21 patients (28.6%), including 10 of 124 regions and 11 of 246 cores, vs targeted biopsy in 10 of 21 (47.6%), including 17 of 50 regions and 40 of 125 cores. Five of 21 patients had positive findings on targeted biopsy only and 1 of 21 had positive findings on template biopsy only. An additional case was upgraded from Grade Group 2 to 3 on targeted biopsy. Extraprostatic disease was detected in 8 of 21 men (38.1%) with histological confirmation in all 3 who underwent lesion biopsy.Conclusions:Fluciclovine positron emission tomography real-time ultrasound fusion guidance for biopsy is feasible in patients with biochemical failure after nonsurgical therapy for prostate cancer. It identifies more recurrent prostate cancer using fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy of recurrent prostate cancer.

AB - We assessed the feasibility and cancer detection rate of fluciclovine (18F) positron emission tomography-ultrasound fusion targeted biopsy vs standard template biopsy in the same patient with biochemical failure after nonsurgical therapy for prostate cancer.Materials and Methods:A total of 21 patients with a mean ± SD prostate specific antigen of 7.4 ± 6.8 ng/ml and biochemical failure after nonoperative prostate cancer treatment underwent fluciclovine (18F) positron emission tomography-computerized tomography (mean 364.1 ± 37.7 MBq) and planning transrectal prostate ultrasound with 3-dimensional image reconstruction. Focal prostatic activity on positron emission tomography was delineated and co-registered with planning ultrasound. During the subsequent biopsy session computer generated 12-core template biopsies were performed and then fluciclovine defined targets were revealed and biopsied. Histological analysis of template and targeted cores were completed.Results:Template biopsy was positive for malignancy in 6 of 21 patients (28.6%), including 10 of 124 regions and 11 of 246 cores, vs targeted biopsy in 10 of 21 (47.6%), including 17 of 50 regions and 40 of 125 cores. Five of 21 patients had positive findings on targeted biopsy only and 1 of 21 had positive findings on template biopsy only. An additional case was upgraded from Grade Group 2 to 3 on targeted biopsy. Extraprostatic disease was detected in 8 of 21 men (38.1%) with histological confirmation in all 3 who underwent lesion biopsy.Conclusions:Fluciclovine positron emission tomography real-time ultrasound fusion guidance for biopsy is feasible in patients with biochemical failure after nonsurgical therapy for prostate cancer. It identifies more recurrent prostate cancer using fewer cores compared with template biopsy in the same patient. Further study is required to determine in what manner targeted biopsy may augment template biopsy of recurrent prostate cancer.

KW - diagnostic imaging

KW - image-guided biopsy

KW - positron emission tomography

KW - prostatic neoplasms

KW - ultrasonography

UR - http://www.scopus.com/inward/record.url?scp=85069295063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069295063&partnerID=8YFLogxK

U2 - 10.1097/JU.0000000000000200

DO - 10.1097/JU.0000000000000200

M3 - Article

C2 - 30817240

AN - SCOPUS:85069295063

VL - 202

SP - 413

EP - 421

JO - Journal of Urology

JF - Journal of Urology

SN - 0022-5347

IS - 2

ER -